Bayer CFO says ‘general market growth trends intact’ for Consumer Health

Looking ahead, CFO Wolfgang Nickl outlined Bayer’s (BAYRY) prospects for 2026, including some comments on the main known business drivers for next year for the three divisions. For example, he pointed to product launches and patent expirations at Pharmaceuticals. Regarding Crop Science, Nickl said: “While the agricultural market outlook remains quite dynamic, we look forward to bringing innovation to farmers and pursuing our profitability goals.” For Consumer Health, he added: “Following some challenges in key markets this year, we see the general market growth trends intact.” The company expects significant currency headwinds to continue in 2026. “Overall, we’re fully focused on effectively managing what we control, adjusting to new realities quickly and advancing in our transformation,” said Nickl. The company will provide specific guidance with the full-year 2025 results at the end of February next year.